sard (Safety and Environmental Protection Division, Brookhaven National Laboratory) have integrated the total clinical experiencecollected by the medical program relating thyroid neoplasia to radiation exposure. It should be noted that the unexposed population statistics were supplied by Dr. Conard andused in their calculations. Included are manyindividuals not in the comparison population. For example, “street surveys” for palpable thyroid lesions were carried out on the islands of Wotje and Likiep. From these and other unselected populations an approximateincidenceof thyroid neoplasia for unexposed Marshallese has been derived. Table 5, on the other hand, is restricted to persons in the exposure groups definedat the outset of this report. to the Marshall Islands medical program. The excellent logistical support of Mr. William Stanley and his staff at the Pacific Area Support Office, Department of Energy, Honolulu,and of the captain and crewof LiktanurI] is sincerely acknowledged. Of particular value to the Marshall Islands medical program has been the highly competent and empathic assistance of Ms. Jenuk Kabua, R.N., and Mr. Helmer Emos, laboratory technician, Brookhaven National Laboratory Marshallese employees. The excellent secretarial services of Ms. Geraldine Callister and the editorial assistance of Ms. Mary Rustad are most appreciated. Dr. V.P. Bond, Associate Director, Brookhaven National Laboratory, kindly reviewed the manuscript. References INDIVIDUAL LABORATORY DATA Theprevious sixty-four Brookhaven National Laboratory Medical Department publications concerning the Marshall Islands fallout expo- As in earlier Brookhaven National Laboratory reports on the findings of the Marshall Islands medical program, a listing of individual laboratory test results obtained at the time of the annual examinations is provided in Appendix IV. This computer-generated listing has been the base for data analysis as performed on a VAX computer using BMDP statistical programs. The data presented were obtained at the time of the annual medical examinations in 1981 and 1982. Laboratory work performed at other times when clinically indicated is not included in the computerlisting. For example,if a woman were found to haveiron-deficiency anemia at the time of an annual examination and was treated with iron, her initial hemoglobin level and not the recovery value would be given in Appendix IV. All test results, however, are found in each person’s active medicalfile. sure are included in the followinglist of refer- ences. They are identified by an asterisk preceding the reference number. Those articles not cited in the text are placed in chronological order at the conclusion of the listing. In addition, several chapters in the third, fourth, and fifth editions of the textbook Atomic Medicine (Williams and Wilkins, Baltimore, MD) were contributed by the Medical Department, Brookhaven National Laboratory, and contain Marshallese data. *1. CONARD,R.A.ETAL., Review of Medical Findings ina Marshallese Population Twenty-Six Years After Accidental Exposure to Radioactive Fallout. BNL 51261, 1980. *2, Conarp, R.A., MEYER, L.M., RALL, J.E., Lowrey, A., Bac, S.A., CANNON, B., CARTER, E.L., EICHER, M., and HecuTer, H., March 1957 Medical Survey of Rongelap and Utirik People Three Years After Exposure to Radioactive Fallout. BNL 501 (T-119), 1958. 3. MANTEL, N., Evaluation of survival data and two new rank orderstatistics arising in its consideration. Cancer Chemother. Rep. 50: 163-70 (1966). 4. Bres.Low, N., A generalized Kruskal-Wallis test for comparing k samples subject to unequal patterns of censorship. Biometrika 57: 579-94 (1970). ’ 5. GRIMSON, R. AND QUADE, D., Asimpletest for equally likely random responsesin a sequence Acknowledgments The authors are grateful to Dr. R.A. Conard (for many years the Principal Investigator of the Marshall Islands Study), Dr. E.P. Cronkite (Senior Scientist, Brookhaven National Laboratory), Dr. B. Dobyns (Departmentof Surgery, Cleveland Metropolitan Hospital), Dr. P.R. Larsen (Massachusetts General Hospital), and Dr. J. Rebbins (Chief, Clinical Endocrinology Branch, the National Institutes of Health) for their continuing support andclinical assistance 16